The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds
Open accessAbstract
Glucocorticoids remain the frontline treatment for inflammatory disorders, yet represent a double-edged sword with beneficial therapeutic actions alongside adverse effects, mainly in metabolic regulation. Considerable efforts were made to improve this balance by attempting to amplify therapeutic beneficial anti-inflammatory actions and to minimize adverse metabolic actions. Most attention has focused on the development of novel compounds favoring the transrepressing actions of the glucocorticoid receptor, assumed to be important for anti-inflammatory actions, over the transactivating actions, assumed to underpin the undesirable actions. These compounds are classified as selective glucocorticoid receptor agonists (SEGRAs) or selective glucocorticoid receptor modulators (SEGRMs). The latter class is able to modulate the activity of a GR agonist and/or may not classically bind the glucocorticoid receptor ligand-binding pocket. SEGRAs and SEGRMs are collectively denominated SEGRAMs (selective glucocorticoid receptor agonists and modulators). Although this transrepression vs transactivation concept proved to be too simplistic, the developed SEGRAMs were helpful in elucidating various molecular actions of the glucocorticoid receptor, but have also raised many novel questions. We discuss lessons learned from recent mechanistic studies of selective glucocorticoid receptor modulators. This is approached by analyzing recent experimental insights in comparison with knowledge obtained using mutant GR research, thus clarifying the current view on the SEGRAM field. These insights also contribute to our understanding of the processes controlling glucocorticoid-mediated side effects as well as glucocorticoid resistance. Our perspective on non-steroidal SEGRAs and SEGRMs considers remaining opportunities to address research gaps in order to harness the potential for more safe and effective glucocorticoid receptor therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068
DNA binding site sequence directs glucocorticoid receptor structure and activity
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., & Yamamoto, K. R. (2009) · Science · doi:10.1126/science.1164265 · Cited by 673
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594 · cited 2×
“These mechanisms typically inhibit the transcription of pro-inflammatory proteins (e.g. cytokines, enzymes and adhesion molecules) (Stahn & Buttgereit, 2008; Beck et al., 2009).”
BackgroundSurjit, M., Ganti, K. P., Mukherji, A., Ye, T., Hua, G., Metzger, D., Li, M., & Chambon, P. (2011) · Cell · doi:10.1016/j.cell.2011.03.027 · Cited by 551 · cited 1×
“Interestingly, an attenuating effect of the GRdimmutation was also retrieved for some genes that were downregulated by classic GCs (Surjit et al., 2011).”
BackgroundAbraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., & Clark, A. R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060336 · Cited by 430 · cited 1×
“Of note, also the dexamethasone-stimulated GRdim mutant is capable of inducing the expression of DUSP1 in COS-7 cells and murine bone marrow macrophages (Abraham et al., 2006; Tchen et al., 2010), albeit not in prednisolone-treated GRdim murine livers (Frijters et al., 2010) .”
BackgroundOakley, R. H., & Cidlowski, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.179325 · Cited by 373
Glucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310
Beck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Self-citation
Cited by
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
Giridharan, S., & Srinivasan, M. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s140188 · Cited by 686
A General Introduction to Glucocorticoid Biology
Timmermans, S., Souffriau, J., & Libert, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01545 · Cited by 609
Self-citationFresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Glucocorticoid therapy and ocular hypertension
Dibas, A., & Yorio, T. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.018 · Cited by 75
Metadata
- Authors
- Sundahl, N., Bridelance, J., Libert, C., De Bosscher, K., & Beck, I. M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 152
- Pages
- 28-41
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W211424878
- Cited by
- 216
- References
- 26
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. https://app.cochat.ai/papers/10.1016/j.pharmthera.2015.05.001
- The paper
- Sundahl, N., Bridelance, J., Libert, C., De Bosscher, K., & Beck, I. M. (2015). Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2015.05.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.